The achievement, which comes 17 years after the birth of Dolly the sheep, represents a major turning point in human cloning research which could now lead to new tissue-transplant operations for a range of debilitating disorders, such as Parkinson's disease, multiple sclerosis, heart disease and spinal cord injuries.
Researchers who made the advance emphasised that the work is designed to produce replacement tissue for transplant operations from a patient's own skin cells, rather than to improve the chances of so-called "reproductive cloning".
The technique used by the team led by Shoukhrat Mitalipov, a senior scientist at Oregon National Primate Research Center (ONPRC), is a variation of the commonly used method called somatic cell nuclear transfer, or SCNT.
It involves transplanting the nucleus of one cell, containing an individual's DNA, into an egg cell that has had its genetic material removed. The unfertilised egg cell then develops and eventually produces stem cells.
The important technical advances by the team enabled the cloned human embryos to survive to the 150-cell stage, known as a blastocyst, when embryonic stem cells can be extracted for growing in the laboratory into specialised tissue cells, such as nerve cells or cardiac muscle.
"Furthermore, because these reprogrammed cells can be generated with nuclear genetic material from a patient, there is no concern of transplant rejection," Mitalipov said.
The research was directly aimed at generating embryonic stem cells for treating serious disorders from a patient's skin cells, and not at improving the chances of producing cloned babies, Mitalipov added.
"This is not our focus, nor do we believe our findings might be used by others to advance the possibility of human reproductive cloning," he said.
The study was published in the journal Cell.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
